Clinical Research Directory
Browse clinical research sites, groups, and studies.
The RECAP2 Study: Midazolam and Psilocybin
Sponsor: University of Wisconsin, Madison
Summary
The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing. Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing. Participants will: * Receive one of four possible combinations of medications * Undergo an MRI * Complete questionnaires * Undergo transcranial magnetic stimulation (TMS) and EEG
Official title: Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-08-07
Completion Date
2027-12
Last Updated
2026-04-03
Healthy Volunteers
Yes
Conditions
Interventions
Psilocybin
25mg of psilocybin
Psilocybin
1mg of psilocybin
Midazolam
The goal of the midazolam dosing regimen is to induce amnesia of the psychedelic experience without inducing over-sedation during the dosing session.
Saline
Saline will be administered as a placebo for midazolam
Locations (1)
UW School of Medicine and Public Health
Madison, Wisconsin, United States